SG11201608882RA - New bispecific format suitable for use in high-through-put screening - Google Patents
New bispecific format suitable for use in high-through-put screeningInfo
- Publication number
- SG11201608882RA SG11201608882RA SG11201608882RA SG11201608882RA SG11201608882RA SG 11201608882R A SG11201608882R A SG 11201608882RA SG 11201608882R A SG11201608882R A SG 11201608882RA SG 11201608882R A SG11201608882R A SG 11201608882RA SG 11201608882R A SG11201608882R A SG 11201608882RA
- Authority
- SG
- Singapore
- Prior art keywords
- format suitable
- put screening
- bispecific format
- new bispecific
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1409558.2A GB201409558D0 (en) | 2014-05-29 | 2014-05-29 | Method |
| PCT/EP2015/061819 WO2015181282A1 (en) | 2014-05-29 | 2015-05-28 | New bispecific format suitable for use in high-through-put screening |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608882RA true SG11201608882RA (en) | 2016-11-29 |
Family
ID=51214419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608882RA SG11201608882RA (en) | 2014-05-29 | 2015-05-28 | New bispecific format suitable for use in high-through-put screening |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10358493B2 (en) |
| EP (2) | EP3750915B1 (en) |
| JP (1) | JP6628741B2 (en) |
| KR (2) | KR102472643B1 (en) |
| CN (2) | CN106459220B (en) |
| AU (2) | AU2015265900B2 (en) |
| BR (2) | BR112016026337B1 (en) |
| CA (1) | CA2949725C (en) |
| CL (1) | CL2016003068A1 (en) |
| CY (1) | CY1124573T1 (en) |
| DK (2) | DK3149032T3 (en) |
| ES (2) | ES2916468T3 (en) |
| GB (1) | GB201409558D0 (en) |
| HR (2) | HRP20220649T1 (en) |
| HU (2) | HUE059106T2 (en) |
| IL (2) | IL248573B (en) |
| LT (2) | LT3750915T (en) |
| MA (2) | MA40252A (en) |
| MX (2) | MX2016014684A (en) |
| MY (1) | MY182625A (en) |
| PL (2) | PL3750915T3 (en) |
| PT (2) | PT3750915T (en) |
| SG (1) | SG11201608882RA (en) |
| SI (2) | SI3149032T1 (en) |
| WO (1) | WO2015181282A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| WO2014001326A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201521391D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521389D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521382D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521393D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| KR20190120782A (en) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Proteins That Bind HER2, NKG2D, and CD16 |
| CN107064092B (en) * | 2017-05-08 | 2019-12-13 | 上海药明生物技术有限公司 | Bispecific antibody biological activity and titer detection method and application thereof |
| WO2019089544A1 (en) * | 2017-11-01 | 2019-05-09 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
| AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
| GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
| CN110669137B (en) * | 2019-10-24 | 2021-07-16 | 高新 | Multi-specificity antibody and preparation method and application thereof |
| US20230125234A1 (en) | 2020-02-13 | 2023-04-27 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
| EP4103608A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
| EP4103611B1 (en) | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
| EP4103612A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
| EP4103609A1 (en) * | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
| CN111473332B (en) * | 2020-04-09 | 2022-02-15 | 浙江集美生物技术有限公司 | Intelligent energy-saving environment-friendly dead pig burning line system |
| EP4154910A1 (en) * | 2020-06-30 | 2023-03-29 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| WO2024022602A1 (en) | 2022-07-28 | 2024-02-01 | Akamis Bio Ltd | Virus encoding transgenes to complement cellular therapy |
| CN115976035B (en) * | 2022-10-14 | 2024-01-09 | 武汉大学 | Adjustable universal CAR, CAR-T cell and fusion guide polypeptide |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (en) | 1987-07-01 | 1987-07-01 | Novo Industri As | immobilization |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE151110T1 (en) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JP3672306B2 (en) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | Heterodimeric receptor library using phagemids |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ATE275198T1 (en) | 1991-12-02 | 2004-09-15 | Medical Res Council | PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| UA40577C2 (en) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| CA2279329C (en) * | 1997-01-31 | 2013-05-21 | Universite De Montreal | Protein fragment complementation assays to detect biomolecular interactions |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| IL139344A0 (en) * | 1998-05-19 | 2001-11-25 | Avidex Ltd | Soluble t cell receptor |
| DE19952956A1 (en) | 1999-11-03 | 2001-05-17 | Acgt Progenomics Ag | Process for the connection of molecular substances |
| ATE273323T1 (en) | 1999-12-28 | 2004-08-15 | Esbatech Ag | INTRABODY WITH DEFINED STRUCTURE (ßFRAMEWORKß) STABLE IN A REDUCING ENVIRONMENT AND THEIR USES |
| GB0103389D0 (en) | 2001-02-12 | 2001-03-28 | Novartis Ag | Organic compounds |
| US20050069538A1 (en) | 2003-09-18 | 2005-03-31 | Gregorio Aversa | Therapeutic binding molecules |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| EP1461081A4 (en) | 2001-12-03 | 2006-05-17 | Abgenix Inc | Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
| ATE482719T1 (en) | 2002-02-21 | 2010-10-15 | Univ Duke | TREATMENT METHODS USING ANTI-CD22 ANTIBODIES |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| EP1413316A1 (en) * | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| GB0225279D0 (en) | 2002-10-30 | 2002-12-11 | Celltech R&D Ltd | Biological products |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| US20050048578A1 (en) | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
| US20040268306A1 (en) | 2003-06-30 | 2004-12-30 | Cheng Ken Prayoon | Methods, systems and computer program products for language independent data communication and display |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
| CN100415765C (en) | 2003-08-07 | 2008-09-03 | 宜康公司 | Methods for humanizing rabbit monoclonal antibodies |
| DE602004026081D1 (en) | 2003-09-18 | 2010-04-29 | Novartis Ag | THERAPEUTIC HUMANIZED ANTIBODIES TO CD45 ISOFORMS |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| EA012622B1 (en) | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Bispecific fusion antibodies with enhanced serum half-life |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US20060018897A1 (en) | 2004-06-28 | 2006-01-26 | Transtarget Inc. | Bispecific antibodies |
| CA2607954A1 (en) | 2005-05-11 | 2006-11-16 | Philogen S.P.A. | Conjugate for targeting of drug |
| US7745393B2 (en) | 2005-11-03 | 2010-06-29 | Jumi Shin | Minimalist bZIP proteins and uses thereof |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
| EP1986689A4 (en) | 2006-01-27 | 2009-09-02 | Cellerant Therapeutics Inc | Compositions and methods for treating haematological proliferative disorders |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| CN101626782B (en) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | Human antibodies that bind cd22 and uses thereof |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| ES2381788T3 (en) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anti-CD79b and immunoconjugate antibodies and methods of use |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| CA2744523A1 (en) | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods and vectors for display of molecules and displayed molecules and collections |
| US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| CA2772572A1 (en) | 2009-08-31 | 2011-03-03 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| US20110250642A1 (en) | 2010-04-12 | 2011-10-13 | Sorrento Therapeutics | Method for Displaying Antibodies |
| MX353144B (en) | 2010-04-20 | 2017-12-20 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof. |
| EP2588123A2 (en) | 2010-06-30 | 2013-05-08 | Compugen Ltd. | C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| ES2537207T3 (en) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| CN103732628B (en) | 2011-03-03 | 2017-06-23 | 酵活有限公司 | Multivalence heteropolymer frame design and construct |
| WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| AU2012328322A1 (en) | 2011-10-27 | 2014-06-12 | Genmab A/S | Production of heterodimeric proteins |
| WO2013078455A2 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Proteomic identification of antibodies |
| CA2853138A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| US20140212425A1 (en) | 2011-12-05 | 2014-07-31 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| WO2014001326A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| CA2873889A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Anti-cd22 antibodies and immunoconjugates |
| MX2015000359A (en) | 2012-07-09 | 2015-04-14 | Genentech Inc | Immunoconjugates comprising anti-cd79b antibodies. |
| ES2661572T3 (en) | 2012-07-09 | 2018-04-02 | Genentech, Inc. | Immunoconjugates comprising anti-CD79b antibodies |
| CN104428007B (en) | 2012-07-09 | 2018-03-16 | 基因泰克公司 | Immunoconjugates comprising anti-CD22 antibody |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| KR101963231B1 (en) | 2012-09-11 | 2019-03-28 | 삼성전자주식회사 | Protein complex for preparing bispecific antibodies and method using thereof |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| RU2015140915A (en) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | BSPECIFIC ANTI-BINDING MOLECULES ACTIVATING T-CELLS |
| UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
| WO2015057834A1 (en) | 2013-10-15 | 2015-04-23 | The California Institute For Biomedical Research | Peptidic chimeric antigen receptor t cell switches and uses thereof |
| CN106029098A (en) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | Humanized RFB4 anti-CD22 antibody |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201411420D0 (en) | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201521393D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521382D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
-
2014
- 2014-05-29 GB GBGB1409558.2A patent/GB201409558D0/en not_active Ceased
-
2015
- 2015-05-28 CN CN201580028405.9A patent/CN106459220B/en active Active
- 2015-05-28 LT LTEP20176103.8T patent/LT3750915T/en unknown
- 2015-05-28 JP JP2016569954A patent/JP6628741B2/en active Active
- 2015-05-28 SI SI201531713T patent/SI3149032T1/en unknown
- 2015-05-28 BR BR112016026337-5A patent/BR112016026337B1/en active IP Right Grant
- 2015-05-28 ES ES20176103T patent/ES2916468T3/en active Active
- 2015-05-28 SG SG11201608882RA patent/SG11201608882RA/en unknown
- 2015-05-28 PL PL20176103.8T patent/PL3750915T3/en unknown
- 2015-05-28 PT PT201761038T patent/PT3750915T/en unknown
- 2015-05-28 HR HRP20220649TT patent/HRP20220649T1/en unknown
- 2015-05-28 CA CA2949725A patent/CA2949725C/en active Active
- 2015-05-28 MX MX2016014684A patent/MX2016014684A/en unknown
- 2015-05-28 WO PCT/EP2015/061819 patent/WO2015181282A1/en active Application Filing
- 2015-05-28 HU HUE20176103A patent/HUE059106T2/en unknown
- 2015-05-28 AU AU2015265900A patent/AU2015265900B2/en active Active
- 2015-05-28 HR HRP20211538TT patent/HRP20211538T1/en unknown
- 2015-05-28 EP EP20176103.8A patent/EP3750915B1/en active Active
- 2015-05-28 MA MA040252A patent/MA40252A/en unknown
- 2015-05-28 LT LTEPPCT/EP2015/061819T patent/LT3149032T/en unknown
- 2015-05-28 SI SI201531849T patent/SI3750915T1/en unknown
- 2015-05-28 PT PT157269234T patent/PT3149032T/en unknown
- 2015-05-28 DK DK15726923.4T patent/DK3149032T3/en active
- 2015-05-28 EP EP15726923.4A patent/EP3149032B1/en active Active
- 2015-05-28 BR BR122020025858-6A patent/BR122020025858B1/en active IP Right Grant
- 2015-05-28 MY MYPI2016704211A patent/MY182625A/en unknown
- 2015-05-28 US US15/311,198 patent/US10358493B2/en active Active
- 2015-05-28 KR KR1020167034620A patent/KR102472643B1/en active IP Right Grant
- 2015-05-28 PL PL15726923T patent/PL3149032T3/en unknown
- 2015-05-28 KR KR1020227041542A patent/KR20220162883A/en not_active Application Discontinuation
- 2015-05-28 ES ES15726923T patent/ES2885815T3/en active Active
- 2015-05-28 HU HUE15726923A patent/HUE056727T2/en unknown
- 2015-05-28 CN CN202110759765.3A patent/CN113480663A/en active Pending
- 2015-05-28 MA MA053624A patent/MA53624A/en unknown
- 2015-05-28 DK DK20176103.8T patent/DK3750915T3/en active
-
2016
- 2016-10-27 IL IL248573A patent/IL248573B/en active IP Right Grant
- 2016-11-09 MX MX2021002826A patent/MX2021002826A/en unknown
- 2016-11-29 CL CL2016003068A patent/CL2016003068A1/en unknown
-
2019
- 2019-05-02 US US16/402,097 patent/US20190322739A1/en not_active Abandoned
-
2020
- 2020-06-29 IL IL275743A patent/IL275743B/en unknown
-
2021
- 2021-03-10 AU AU2021201515A patent/AU2021201515B2/en active Active
- 2021-10-07 CY CY20211100875T patent/CY1124573T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275743B (en) | New bispecific format suitable for use in high-through-put screening | |
| SG11201704577TA (en) | Bispecific antibodies against cd3epsilon and bcma | |
| GB2517844B (en) | Thwarting traffic analysis | |
| SG11201700551TA (en) | Bispecific antibodies against cd3epsilon and bcma | |
| HUE047032T2 (en) | Transport block size determination | |
| GB201412018D0 (en) | [Apparatus | |
| PL3261878T3 (en) | Cargo securing apparatus | |
| GB201515024D0 (en) | Comfort apparatus | |
| SI3218720T1 (en) | Biomarkers for disease progression in melanoma | |
| SG10201502212RA (en) | Urinal apparatus | |
| GB201416015D0 (en) | Biomarker | |
| GB201411567D0 (en) | Quantification methods | |
| GB201420239D0 (en) | Biomarker | |
| PL2910913T3 (en) | Method and arrangement for providing weighing results | |
| IL233012A0 (en) | Georaphic reference-scenario for responders | |
| GB201409060D0 (en) | Screening method | |
| GB201406939D0 (en) | Screening method | |
| GB201415337D0 (en) | Screening methods for ATP13A2 activators | |
| GB201411343D0 (en) | Biomarker | |
| GB201409793D0 (en) | Biomarker | |
| GB201403564D0 (en) | Biomarker | |
| GB201402166D0 (en) | Biomarker | |
| GB201401679D0 (en) | Biomarker | |
| GB201407878D0 (en) | Macerator deodoriser apparatus | |
| GB201405257D0 (en) | Cargo securing apparatus |